Cited 7 times in
Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정지예 | - |
dc.date.accessioned | 2016-02-04T11:12:53Z | - |
dc.date.available | 2016-02-04T11:12:53Z | - |
dc.date.issued | 2015 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/139921 | - |
dc.description.abstract | Two once-daily inhaled bronchodilators, indacaterol and tiotropium, are widely used as first-line therapy in stable COPD patients. This study was performed to compare the clinical efficacy and safety between indacaterol and tiotropium in patients with moderate-to-severe COPD. MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were searched to identify all published randomized controlled trials (RCTs). The primary outcome was trough forced expiratory volume in 1 second (FEV1) at week 12. Four RCTs were eligible for inclusion (three RCTs with moderate-to-severe COPD patients and one RCT with only severe COPD patients). Trough FEV₁ at weeks 12 and 26 were not significantly different between indacaterol and tiotropium by the standardized mean difference with 0.014 (95% CI, -0.036, 0.063, I²= 23.5%) and with 0.037 (95% CI, -0.059 to 0.133, I²= 0%) along with differences in means of 0.003L and 0.014L, respectively. Indacaterol and tiotropium also showed similar St. George's Respiratory Questionnaire (SGRQ) total scores and percentages of patients with SGRQ improvement (≥ 4 units) at week 26. The incidences of nasopharyngitis, serious cardiovascular events, and serious adverse events were not different between indacaterol and tiotropium, while those of cough (OR = 1.68, P < 0.001, and RR = 1.63) and COPD worsening (OR = 1.18, P = 0.003, and RR = 1.12) were higher for indacaterol than tiotropium. However, when one study with only severe COPD patients was removed from the meta-analysis, the difference in the incidence of COPD worsening between indacaterol and tiotropium became non-significant (OR = 1.13, P = 0.204, and RR = 1.09). The clinical efficacy and serious adverse events between indacaterol and tiotropium were equivocal in patients with moderate-to-severe COPD. Cough is a common complaint associated with indacaterol, and COPD worsening needs to be carefully monitored in severe COPD patients when treated with indacaterol. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | e0119948 | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adrenergic beta-2 Receptor Agonists/therapeutic use | - |
dc.subject.MESH | Bronchodilator Agents/therapeutic use | - |
dc.subject.MESH | Forced Expiratory Volume/drug effects | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Indans/therapeutic use* | - |
dc.subject.MESH | Pulmonary Disease, Chronic Obstructive/drug therapy* | - |
dc.subject.MESH | Quinolones/therapeutic use* | - |
dc.subject.MESH | Randomized Controlled Trials as Topic | - |
dc.subject.MESH | Tiotropium Bromide/therapeutic use* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trials | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Jung Soo Kim | - |
dc.contributor.googleauthor | Jinkyeong Park | - |
dc.contributor.googleauthor | Seong Yong Lim | - |
dc.contributor.googleauthor | Yeon-Mok Oh | - |
dc.contributor.googleauthor | Kwang Ha Yoo | - |
dc.contributor.googleauthor | Yong Bum Park | - |
dc.contributor.googleauthor | Seung Soo Sheen | - |
dc.contributor.googleauthor | Min-Ji Kim | - |
dc.contributor.googleauthor | K. C. Carriere | - |
dc.contributor.googleauthor | Ji Ye Jung | - |
dc.contributor.googleauthor | Hye Yun Park | - |
dc.identifier.doi | 10.1371/journal.pone.0119948 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03735 | - |
dc.relation.journalcode | J02540 | - |
dc.identifier.eissn | 1932-6203 | - |
dc.identifier.pmid | 25799171 | - |
dc.contributor.alternativeName | Jung, Ji Ye | - |
dc.contributor.affiliatedAuthor | Jung, Ji Ye | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 10 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | e0119948 | - |
dc.identifier.bibliographicCitation | PLOS ONE, Vol.10(3) : e0119948, 2015 | - |
dc.identifier.rimsid | 48380 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.